News

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux.

“Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established a strong track record at leading diagnostics companies,” said Donna Edmonds, BRAINBox Solutions CEO. “He is well positioned to lead the commercial planning and launch for our BRAINBox TBI concussion diagnostic/prognostic tests.”

“BRAINBox has a unique opportunity to change the standard of care for concussion management with its BRAINBox TBI tests, the first objective tests for the diagnosis and risk of long-term complications,” said Mr. Noel. “The company has built an outstanding foundation with product and clinical development and strong relationships with key thought leaders in neurology and emergency medicine. I look forward to working with the team to bring these promising tests to clinicians and patients.”

Mr. Noel began his career in diagnostics at bioMérieux as a market analyst in the BioFire diagnostics unit, rising to Global Product Manager, where he served as global product leader for numerous syndromic molecular diagnostic panels, analyzers and software solutions. At Lumira, he served as Senior Director of Marketing, North America, where he led the marketing strategy and launch of the company’s novel SARS-CoV-2 Ag test during the Covid pandemic. He spearheaded the marketing strategy for the company’s North American point-of-care business, launching and scaling it from $0 to $440 million in revenue within 24 months. Following LumiraDx’s acquisition by Roche Diagnostics in 2024, he guided the full integration of the LumiraDx commercial business and roadmap.

Before entering the diagnostics industry, Mr. Noel taught honors physics, chemistry, and cognitive neuroscience. He holds a Master’s degree in Business and Biotechnology from the University of Utah and a Bachelor’s degree in Psychology from UC San Diego.

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia. …

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three …

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and …